Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agree

76.00
+0.17000.22%
Post-market: 76.000.00000.00%19:17 EDT
Volume:899.45K
Turnover:68.55M
Market Cap:8.13B
PE:42.70
High:76.92
Open:76.09
Low:75.75
Close:75.83
Loading ...

Agree Realty sees FY25 AFFO $4.26-$4.30, consensus $4.30

TIPRANKS
·
12 Feb

Agree Realty Q4 2024 FFO $1.04 Beats $1.02 Estimate, Sales $160.734M Beat $156.368M Estimate

Benzinga
·
12 Feb

BRIEF-Agree Realty Q4 EPS USD 0.41 Vs. IBES Estimate USD 0.43

Reuters
·
12 Feb

Agree Realty Q4 Core Ffo per Share USD 1.02

THOMSON REUTERS
·
12 Feb

Agree Realty Corporation Reports Fourth Quarter and Full Year 2024 Results

PR Newswire
·
12 Feb

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Business Wire
·
11 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
10 Feb

Agree Realty Corp expected to post earnings of 43 cents a share - Earnings Preview

Reuters
·
08 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Feb

Better Monthly Dividend Stock: Realty Income vs. Agree Realty

Motley Fool
·
07 Feb

Agree Realty Maintains Monthly Dividend at $0.253 Per Share; Payable March 14 to Shareholders of Record on Feb. 28

MT Newswires Live
·
07 Feb

Agree Realty Declares Monthly Common and Preferred Dividends

THOMSON REUTERS
·
07 Feb

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire
·
05 Feb

Agree Realty price target lowered to $74 from $76 at Barclays

TIPRANKS
·
04 Feb

Agree Realty Corp. : Barclays Cuts Target Price to $74 From $76

THOMSON REUTERS
·
04 Feb